Email Updates

You are here

Home»Resources

Webinar & Meeting Reports

  • VOICE - What are the implications for rectal microbicide research?

    April 8, 2013

    Jeanne Marrazzo (VOICE protocol co-chair) and Ian McGowan (co-principal investigator of the Microbicide Trials Network) discussed the VOICE results and what they mean for the rectal microbicide field moving forward. This call was presented through a collaboration between IRMA and AVAC.

  • Introduction to Cure Research

    April 2, 2013

    In the wake of exciting new data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, AVAC hosted a webinar to review the current status on research towards an HIV/AIDS cure. The webinar featured Steven Deeks, MD, a researcher at the University of California, San Francisco, who discussed the latest research and what to look forward to in coming years, followed by a Q&A.

  • Treatment as Prevention: Evidence from Europe and beyond

    March 28, 2013

    This was the third webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC. We were joined by an expert panel discussing treatment as prevention, who took questions following their presentations. To view the full Flash animation of the webinar, click here.

  • Global Investments in HIV Treatment Research & Development in 2010 and 2011

    March 15, 2013

    The Treatment Action Group (TAG) and AVAC recently released their latest report, Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011. The report, supported by UNAIDS, found US$2.6 billion was invested in HIV treatment research and development (R&D) in 2011.

  • VOICE Trial Results and Implications for Future Research

    March 11, 2013

    Results from the three-arm HIV prevention trial VOICE – Vaginal and Oral Interventions to Control the Epidemic – were recently presented at the 20th Conference on Retroviruses and Opportunistic Infections. The data showed that none of three interventions tested—daily oral tenofovir, daily oral TDF/FTC (Truvada), and daily 1% vaginal tenofovir gel—provided additional protection against HIV in this study, likely because few of the women in the trial used the products as directed.

  • Conference on Retroviruses and Opportunistic Infections

    March 3, 2013 to March 6, 2013

    The 20th Conference on Retroviruses and Opportunistic Infections (CROI) is a meeting of the world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic.

  • NAM-AVAC Microbicides Webinar

    February 26, 2013

    This 90-minute webinar examined the current state of research into topical microbicides – gels, lubes and devices that can be used to prevent HIV transmission during sex. It provided advocates with an overview of global and European topical microbicide research. The presentations were followed by a question and answer session with our expert speakers.

  • European Contributions to the Search for an HIV Vaccine

    January 29, 2013

    This 90-minute webinar, moderated by Rebekah Webb, provided advocates with an overview of European efforts to develop an HIV vaccine through national and EU-funded programmes. The presentations were followed by a question and answer session with the expert speakers.

  • Beyond Daily Oral TDF/FTC as PrEP: Exploring new drugs and regimens for PrEP

    October 3, 2012

    PrEP researchers discussed ongoing trials of new oral PrEP interventions, including non-daily regimens (also described as “intermittent PrEP”) and new drugs such as maraviroc.

  • United States Conference on AIDS

    September 30, 2012

    The United States Conference on AIDS (USCA) is set for September 30 - October 3, 2012 at Caesars Palace Hotel in Las Vegas, NV. For nearly two decades, USCA has sought “to increase the strength and diversity of the community-based response to the HIV/AIDS epidemic through education, training, new partnerships, collaboration and networking. This year, USCA will work to highlight the changes in our movement that have brought us closer than ever to ending the epidemic, and ways that we can move forward as a community to make this dream a reality.

Pages